当前位置:药药网 / 药品研发 / 美国药品上市后承诺数据库
RAGWITEK, Short Ragweed Pollen Allergen Extract
药品名称
RAGWITEK, Short Ragweed Pollen Allergen Extract
承诺描述
Conduct study, protocol #P008, under PREA to evaluate both safety and efficacy of RAGWITEK as immunotherapy for the treatment of short ragweed pollen-induced allergic rhinitis, with or without conjunctivitis, confirmed by positive skin test or in vitro testing for pollen specific IgE antibodies for short ragweed pollen in pediatric subjects aged 5 to 17 years.
承诺状态描述
The final report was submitted to FDA on 07/3/2019